CL2018002698A1 - Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a - Google Patents
Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5aInfo
- Publication number
- CL2018002698A1 CL2018002698A1 CL2018002698A CL2018002698A CL2018002698A1 CL 2018002698 A1 CL2018002698 A1 CL 2018002698A1 CL 2018002698 A CL2018002698 A CL 2018002698A CL 2018002698 A CL2018002698 A CL 2018002698A CL 2018002698 A1 CL2018002698 A1 CL 2018002698A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- inflammatory diseases
- activity inhibitors
- activity
- inhibitors
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17164573 | 2017-04-03 | ||
| EP17177657 | 2017-06-23 | ||
| EP17189938 | 2017-09-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018002698A1 true CL2018002698A1 (es) | 2018-12-07 |
Family
ID=61024731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018002698A CL2018002698A1 (es) | 2017-04-03 | 2018-09-24 | Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a |
Country Status (17)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101463631B1 (ko) | 2006-03-31 | 2014-11-19 | 추가이 세이야쿠 가부시키가이샤 | 항체의 혈중 동태를 제어하는 방법 |
| RU2510400C9 (ru) | 2007-09-26 | 2014-07-20 | Чугаи Сейяку Кабусики Кайся | Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr |
| US20110111406A1 (en) | 2008-04-11 | 2011-05-12 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| WO2012073992A1 (ja) | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
| AR103161A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso |
| AR103162A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-c5 y métodos para su uso |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES |
| ES2893769T3 (es) | 2017-04-03 | 2022-02-10 | Inflarx Gmbh | Tratamiento de enfermedades inflamatorias con inhibidores de la actividad de C5a |
| US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| EP3642230A1 (en) * | 2017-06-23 | 2020-04-29 | InflaRx GmbH | Treatment of inflammatory diseases with inhibitors of c5a activity |
| ES2943492T3 (es) | 2018-11-30 | 2023-06-13 | Chemocentryx Inc | Formulación de cápsulas |
| CN113543796A (zh) * | 2019-03-08 | 2021-10-22 | Ra制药公司 | 齐鲁考普作为深层组织穿透性c5抑制剂 |
| CN119874606A (zh) | 2019-03-11 | 2025-04-25 | 因弗拉克斯有限责任公司 | 作为C5a受体调节剂的稠合哌啶基双环和相关化合物 |
| EP3958842A1 (en) * | 2019-04-24 | 2022-03-02 | RA Pharmaceuticals, Inc. | Compositions and methods for modulating complement activity |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| KR20230045075A (ko) * | 2020-08-12 | 2023-04-04 | 이나뜨 파르마 에스.에이. | 아브도랄리맙을 사용한 피하 항-C5aR 길항제 치료 용법 |
| CN116529241A (zh) * | 2020-10-28 | 2023-08-01 | 坎莫森特里克斯公司 | 治疗化脓性汗腺炎的方法 |
| JP2023548117A (ja) * | 2020-10-28 | 2023-11-15 | ケモセントリックス， インコーポレイテッド | 化膿性汗腺炎を処置する方法 |
| AU2022207985A1 (en) | 2021-01-13 | 2023-07-06 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
| CN116036233A (zh) * | 2023-01-10 | 2023-05-02 | 中山大学附属第八医院（深圳福田） | 小分子化合物pmx 53在制备抑制血管钙化和血管纤维化药物中的应用 |
| US12180274B2 (en) | 2023-05-26 | 2024-12-31 | Inflarx Gmbh | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| AUPO755097A0 (en) | 1997-06-25 | 1997-07-17 | University Of Queensland, The | Receptor agonist and antagonist |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| AUPR833401A0 (en) | 2001-10-17 | 2001-11-08 | University Of Queensland, The | G protein-coupled receptor antagonists |
| US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| EP2578683B9 (en) | 2004-02-12 | 2015-04-15 | Archemix LLC | Aptamer therapeutics useful in the treatment of complement-related disorders |
| CA2658352A1 (en) | 2006-07-21 | 2008-01-24 | Promics Pty Ltd | Treatment for intimal hyperplasia and related conditions |
| RU2009110154A (ru) * | 2006-08-22 | 2010-09-27 | Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) | АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ |
| GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| SG172338A1 (en) | 2008-12-22 | 2011-07-28 | Chemocentryx Inc | C5ar antagonists |
| US9290736B2 (en) * | 2009-11-04 | 2016-03-22 | Case Western Reserve University | Compositions and methods of treating T cell mediated disorder |
| EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| HRP20171176T1 (hr) | 2010-06-24 | 2017-10-06 | Chemocentryx, Inc. | C5ar antagonisti |
| EP3312281A3 (en) | 2013-03-14 | 2018-06-27 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| JP6718379B2 (ja) * | 2014-03-20 | 2020-07-08 | インフラルクス ゲーエムベーハー | ウイルス性肺炎治療のためのＣ５ａの阻害剤 |
| WO2016044419A1 (en) | 2014-09-16 | 2016-03-24 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| ES2719876T3 (es) | 2014-10-15 | 2019-07-16 | Alexion Pharma Inc | Métodos para replicar un cultivo celular de producción de eculizumab a gran escala |
| FR3030515B1 (fr) * | 2014-12-23 | 2017-01-20 | Galderma Res & Dev | Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines |
| JP2018520139A (ja) | 2015-06-26 | 2018-07-26 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | エクリズマブまたはエクリズマブバリアントでのワクチン接種に従って患者を処置するための方法 |
| JP7121722B2 (ja) | 2016-04-04 | 2022-08-18 | ケモセントリックス，インコーポレイティド | 可溶性Ｃ５ａＲアンタゴニスト |
| ES2893769T3 (es) * | 2017-04-03 | 2022-02-10 | Inflarx Gmbh | Tratamiento de enfermedades inflamatorias con inhibidores de la actividad de C5a |
| US10376595B2 (en) * | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| CN119874606A (zh) | 2019-03-11 | 2025-04-25 | 因弗拉克斯有限责任公司 | 作为C5a受体调节剂的稠合哌啶基双环和相关化合物 |
-
2018
- 2018-01-03 ES ES18701250T patent/ES2893769T3/es active Active
- 2018-01-03 MX MX2019011825A patent/MX2019011825A/es unknown
- 2018-01-03 WO PCT/EP2018/050146 patent/WO2018184739A1/en not_active Ceased
- 2018-01-03 EP EP23179884.4A patent/EP4272821A3/en active Pending
- 2018-01-03 AU AU2018249310A patent/AU2018249310A1/en not_active Abandoned
- 2018-01-03 KR KR1020197031043A patent/KR20190138806A/ko not_active Ceased
- 2018-01-03 CN CN201880037003.9A patent/CN111108118A/zh active Pending
- 2018-01-03 EP EP21197604.8A patent/EP3978523A1/en active Pending
- 2018-01-03 TW TW107100139A patent/TWI826364B/zh active
- 2018-01-03 DK DK18701250.5T patent/DK3411400T3/da active
- 2018-01-03 IL IL261809A patent/IL261809B2/en unknown
- 2018-01-03 TW TW112106878A patent/TW202348249A/zh unknown
- 2018-01-03 EP EP18701250.5A patent/EP3411400B1/en active Active
- 2018-01-03 SG SG11201807998WA patent/SG11201807998WA/en unknown
- 2018-01-03 JP JP2020502768A patent/JP7486415B2/ja active Active
- 2018-01-03 CA CA3058023A patent/CA3058023A1/en active Pending
- 2018-01-03 PL PL18701250T patent/PL3411400T3/pl unknown
- 2018-06-13 US US16/007,634 patent/US11273225B2/en active Active
- 2018-09-24 CL CL2018002698A patent/CL2018002698A1/es unknown
-
2019
- 2019-10-02 ZA ZA2019/06485A patent/ZA201906485B/en unknown
-
2022
- 2022-08-10 JP JP2022127667A patent/JP2022176946A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| TWI826364B (zh) | 2023-12-21 |
| EP3411400A1 (en) | 2018-12-12 |
| AU2018249310A1 (en) | 2019-10-17 |
| ES2893769T3 (es) | 2022-02-10 |
| SG11201807998WA (en) | 2018-12-28 |
| JP2022176946A (ja) | 2022-11-30 |
| KR20190138806A (ko) | 2019-12-16 |
| IL261809B2 (en) | 2024-04-01 |
| JP2020515643A (ja) | 2020-05-28 |
| CA3058023A1 (en) | 2018-10-11 |
| US20180282425A1 (en) | 2018-10-04 |
| EP3411400B1 (en) | 2021-09-22 |
| IL261809A (en) | 2018-11-29 |
| WO2018184739A1 (en) | 2018-10-11 |
| IL261809B1 (en) | 2023-12-01 |
| PL3411400T3 (pl) | 2021-12-20 |
| DK3411400T3 (da) | 2021-10-11 |
| MX2019011825A (es) | 2020-12-11 |
| EP4272821A3 (en) | 2024-01-03 |
| EP3978523A1 (en) | 2022-04-06 |
| CN111108118A (zh) | 2020-05-05 |
| TW201836641A (zh) | 2018-10-16 |
| EP4272821A2 (en) | 2023-11-08 |
| ZA201906485B (en) | 2021-08-25 |
| TW202348249A (zh) | 2023-12-16 |
| US11273225B2 (en) | 2022-03-15 |
| JP7486415B2 (ja) | 2024-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018002698A1 (es) | Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a | |
| IL272410A (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
| CL2019001874A1 (es) | Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos. | |
| CY1122344T1 (el) | Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων | |
| CY1122184T1 (el) | Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη | |
| EP3596163A4 (en) | CARBON AND ELASTOMER INTEGRATION | |
| MX378686B (es) | Composiciones que comprenden cepas bacterianas. | |
| MX389707B (es) | Neurotoxinas quimericas. | |
| BR112018009706A8 (pt) | composições compreendendo cepas bacterianas | |
| BR112018009213A2 (pt) | composições compreendendo cepas bacterianas | |
| BR112017025003A2 (pt) | composições compreendendo cepas bacterianas | |
| ECSP17018120A (es) | Triazolopirazinonas como inhibidores de pde1 | |
| EP3781188A4 (en) | ADOPTIVE CELL THERAPY | |
| TR201810635T4 (tr) | Anti-jagged1 antikorları ve kullanım yöntemleri. | |
| DOP2017000254A (es) | Imidazopirazinonas como inhibidores de pde1 | |
| EP3635295C0 (de) | Korpusmöbel | |
| MX2019009908A (es) | Combinacion de un agonista de ppar con un agonista de fxr. | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| DOP2016000263A (es) | Quinazolin-thf-aminas halogenadas como inhibidores de pde1 | |
| ECSP16071574A (es) | Hexahidrofuropirroles como inhibidores de pde1 | |
| PL3441639T3 (pl) | Zespół tłumika i przeznaczony do niego tłumik | |
| IL271703B (en) | Use of macroazapyridinophanes metal complexes in the treatment of diseases | |
| UA39584S (uk) | Сережки | |
| AU201715200S (en) | Mirror | |
| EA201990509A1 (ru) | Применения ингибитора лизилоксидазаподобного белка 2 |